De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis
Condition: Graft-versus-host Disease Interventions: Drug: Cyclophosphamide; Drug: Tacrolimus; Drug: Mycophenolate Mofetil; Drug: Ruxolitinib Sponsor: Medical College of Wisconsin Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 18, 2022 Category: Research Source Type: clinical trials
Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD
Condition: Graft Vs Host Disease Interventions: Drug: Cyclophosphamide; Drug: Abatacept; Drug: Tacrolimus Sponsor: NYU Langone Health Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 18, 2022 Category: Research Source Type: clinical trials
De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis
Condition: Graft-versus-host Disease Interventions: Drug: Cyclophosphamide; Drug: Tacrolimus; Drug: Mycophenolate Mofetil; Drug: Ruxolitinib Sponsor: Medical College of Wisconsin Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 18, 2022 Category: Research Source Type: clinical trials
Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD
Condition: Graft Vs Host Disease Interventions: Drug: Cyclophosphamide; Drug: Abatacept; Drug: Tacrolimus Sponsor: NYU Langone Health Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 18, 2022 Category: Research Source Type: clinical trials
De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis
Condition: Graft-versus-host Disease Interventions: Drug: Cyclophosphamide; Drug: Tacrolimus; Drug: Mycophenolate Mofetil; Drug: Ruxolitinib Sponsor: Medical College of Wisconsin Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 18, 2022 Category: Research Source Type: clinical trials
Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD
Condition: Graft Vs Host Disease Interventions: Drug: Cyclophosphamide; Drug: Abatacept; Drug: Tacrolimus Sponsor: NYU Langone Health Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 18, 2022 Category: Research Source Type: clinical trials
De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis
Condition: Graft-versus-host Disease Interventions: Drug: Cyclophosphamide; Drug: Tacrolimus; Drug: Mycophenolate Mofetil; Drug: Ruxolitinib Sponsor: Medical College of Wisconsin Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 18, 2022 Category: Research Source Type: clinical trials
Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD
Condition: Graft Vs Host Disease Interventions: Drug: Cyclophosphamide; Drug: Abatacept; Drug: Tacrolimus Sponsor: NYU Langone Health Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 18, 2022 Category: Research Source Type: clinical trials
Safety, Tolerability and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B
Conditions: Dry Eye; Keratoconjunctivitis Sicca; Ocular Inflammation Interventions: Device: punctum plug insertion; Drug: Eye Drops, Lubricant Sponsor: Eximore Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 16, 2022 Category: Research Source Type: clinical trials
